JOINT WORKING

 

Joint Working

We have a long history of working in partnership with others. Indeed, some of our greatest achievements have come about through collaborative effort.

The Department of Health (DH) defines joint working between the NHS and the pharmaceutical industry as situations where, for the benefit of patients, one or more pharmaceutical companies and the NHS pool skills, experience and/or resources for the joint development and implementation of patient-centred projects and share a commitment to successful delivery. Our ability to continue with our long-standing collaborative efforts pivots on the DH’s joint working mandate and enables us to discover and invent new ways, every day, to help the world be well.

We're currently working with the NHS in numerous ways, across various disciplines and disease areas. Whether it's cost reductions, improved quality of patient care or access to the latest research in a specialist area, we do what we can to help.


Our Joint Working Partnerships​​

Executive Summary

This is the executive summary of the joint working agreement between Merck Sharp and Dohme Limited (MSD) and the South London Health Innovation Network. This agreement lasts from April 2015 to October 2015.

Project Title:

The improvement of integration care pathways for the arrangement of unscheduled care in hypoglycaemia and hyperglycaemia (South London Health Innovation Network Hypo Pathway Project).

Aims and objectives:

In October 2012, LAS launched a new pathway in which GPs are informed within 24-48hrs (with patient consent) where an ambulance crew has treated a hypoglycaemic episode on scene (no hospital conveyance). LAS identified a need to evaluate implementation of this pathway and it was agreed that the Health Innovation Network would provide the capacity and expertise to support this evaluation. It was decided that, using the results of the evaluation, HIN and LAS would then work with service users and providers across the 12 South London CCGs to improve the pathway and in this way deliver enhanced patient outcomes.

The objective of the project is to maximise the benefits of the hypo/hyperglycaemic pathway and ensure that patients receive integrated and tailored care to reduce the risk of these events occurring, many of which are avoidable and increase referral rates to 100%.

Benefits to the Patient:

Through the enhanced knowledge and confidence of LAS staff attending to patients, the recording of information in a standardised way and the subsequent follow up by designated HCPs, patients will have access to a better, more cohesive standard of care and it is anticipated will have better outcomes as a result.

Benefits to the Partner Organisations:

HIN - This project directly helps the South London Health Innovation Network to attain their goal of delivering cross boundary working within their membership to improve health outcomes for South London residents.

LAS – This project helps LAS by working to reduce the number of avoidable hypoglycaemic episodes and by providing the reassurance that patients will receive optimal follow up care after ambulance staff have delivered treatment on scene.

Benefits to MSD:

  • Engagement in this structured Joint Working Project supports MSD’s patient centric approach. MSD’s reputation as a trusted and valued partner will be enhanced.
  • MSD will have an established working relationship with the South London Health Innovation Network. • This project raises awareness of Hypoglycaemia amongst clinicians, which is in line with our current diabetes franchise strategy.

Project Title:

NHS Southwest Long Acting Reversible Contraception (LARC) Implementation Project

Description:

NHS South West, MSD and Bayer HealthCare are working in partnership to achieve region-wide implementation of National Institute for Health and Clinical Excellence (NICE) LARC Guidance, October 2005. This collaborative project aims to impact on region-wide teenage pregnancy rates, unintended pregnancy rates and abortion rates.

Expected benefit to patients:

Better access to the full range of contraceptive options and increased support to areas of highest need to help reduce health inequalities.

Completion date:

March 2012

Project Title:

Primary Care Diabetes Facilitator Project

Description:

The parties involved are working together to increase management of diabetes in Primary Care, to reduce unplanned hospital admissions, to improve early identification of patients at high risk of developing diabetes, to ensure prescription of diabetes medicines in line with NICE recommendations, to improve compliance and frequency of medical reviews and to improve the cost effectiveness of current services within the NHS.

Expected benefit to patients:

Better management of diabetes in Primary Care, fewer unplanned hospital admissions, early identification and subsequent advice on making a positive lifestyle choice and an overall benefit from the improvements to the cost-effectiveness of NHS services.

Completion date:

End of 2012

Project Title:

NHS Nottingham City and Industry Maximising Resources and Outcomes in Diabetes (NIMROD)

Description:

NIMROD will seek to understand why the rates for diabetes-related hospital admissions in Nottingham City are higher than national average and then take steps to reduce the number of avoidable hospital admissions for people with diabetes and diabetes-related illness.

Expected benefit to patients:

Aside from benefits gained from increased quality and efficiency, patients are expected to benefit from a reduction in avoidable hospital admissions in Nottingham and from the programme's objective to ensure that all patients with diabetes in Nottingham City are treated in line with current best national practice i.e.NICE and local clinical guidelines.

Completion date:

End of 2012

Executive Summary

This is the executive summary of the joint working agreement between Merck, Sharp and Dohme Limited (MSD) and London Sexual Health Programme (NHS England, London) and Bayer HealthCare.

Project Title:

Improving Choices in Contraception through Training

Aims and Objectives

This partnership is designed to support NHS London in the implementation of NICE LARC Guidelines (NICE CG30, published in 2005) with peripatetic trainers delivering training and education to Healthcare Professionals in their practices in London.

Benefits to the Patient

Improved access to LARC, in particular, intrauterine system (“IUS”), intrauterine device (“IUD”) and subdermal implant (“SDI”).

Enable patients to make a more informed decision when choosing contraception appropriate to their lifestyle.

Reduction in unintended pregnancies in women of all age groups and termination of pregnancy (TOP) rates.

Benefits to London Sexual Health Programme (NHS England, London)

Reduced variation in Long Acting Reversible Contraception (“LARC”) uptake across NHS London by focusing on areas of low uptake and limited access to LARC.

Upskilling, training and delivery of LARC training to healthcare professionals in London to the nationally recognised standards set by the Faculty of Sexual and Reproductive Healthcare (“FSRH”) and the Royal College of Nurses (“RCN”).

Increase the number of fitters of three LARC methods equally (IUS, IUD, SDI), from both doctors and nurses across boroughs within NHS London. Fitters will also be trained on how to remove the LARC.

Reduction in unintended pregnancies in women of all age groups and termination of pregnancy (TOP) rates.

Benefits to MSD

Increased uptake of each of the three LARC methods (IUS, IUD and SDI) by the implementation of the NICE Guideline on Long Acting Reversible Contraception (CG30) within general practice and sexual and reproductive health services.

Both MSD and Bayer manufacture a LARC method and therefore increasing LARC uptake will benefit all Parties of the Joint Project Group.

Actively demonstrate the added value that MSD can bring to patients and the NHS through collaborative working which utilises MSD's skills, experience and resources.

Completion Date

March 2015

Project Title:

Transforming Community Services in Diabetes - Developing Skills and Competencies in Primary and Community Care

Description:

This programme has been designed to develop the skills of staff in primary and community care. It will utilise skills and expertise from within the pharmaceutical industry combined with the Care Trust Plus's knowledge of the community in Blackburn to deliver improved services on a local basis.

Expected benefit to patients:

By up-skilling and training Healthcare Professionals (HCPs), healthcare will be improved in the Blackburn area which will ultimately reduce hospital admissions, re-admissions and referrals.

Completion date:

End of June 2012

Project Title:

Adult Diabetes Service Project

Description:

The contributors to this project are working together to redesign the provision of diabetes primary care to provide a service that is not only accessible, fair, equitable and personalised. These improvements will be implemented in the hope of reducing inequalities and making the best use of available resources.

Expected benefit to patients:

Greater access to diabetes care in Central Lancashire, in a way that allows greater choice of care to suit individual needs and circumstances.

Completion date:

End of 2012

Project Title:

Department of Health (DoH) supported Pathfinder Project on Public and Patient Engagement (PPE). Branded locally as 'myNHS myVoice'.

Description:

This project aims to deliver a feasibility study that will enable Clinical Commissioning Groups (CCGs) to better understand their population and work with the local population to develop future services.

Expected benefit to patients:

With the aim to recruit 5,000 people to myNHS myVoice (the Leodis Patient Panel), patients are expected to benefit from being given the choice to engage on subject in which they had a personal interest or involvement, as well as an increased awareness of the potential for future, service shaping, involvement. Patients will have greater influence on pathway redesign as well as commissioning and will help to develop a service in which they are involved in a way that suits them.

Completion date:

30th April 2012

Project Title:

Pulmonary Advancement Network for Newark and Sherwood Health (PANNASH)

Description:

This project aims to enhance primary care and treatment received at home for sufferers of Chronic Obstructive Pulmonary Disease (COPD). The project will also aim to improve the abilities of Newark and Sherwood CCG Healthcare providers.

Expected benefit to patients:

Reduction in emergency hospital admissions and better health for people suffering from COPD

Completion date:

July 2012

Executive Summary

This is the executive summary of the joint working agreement between Merck, Sharp and Dohme Limited (MSD) and South East Coast Ambulance Service, Surrey Downs CCG & North West Surrey CCG.

Project Title:

Reducing Repeat Ambulance calls for Diabetic Hypoglycaemia – The Surrey Hypo Pathway project.

Aims and Objectives

The aim of the project is to improve the care of patients living with diabetes (type 1 and type 2) by reducing avoidable episodes of severe hypoglycaemia, through increasing disease review and more effective aftercare following a hypoglycaemic event.

Improved identification, recording and reporting of non-conveyed and conveyed patients suffering hypoglycaemic episodes by the ambulance service will result in better diabetes related health outcomes.

The project involves developing robust clinical management pathways between South East Coast Ambulance Service (SECAmb) and both primary care and community diabetes providers.

Benefits to the patient

Improved communication between healthcare professionals and timely patient follow up will ensure that patients at risk of further hypoglycaemic events are followed up and managed more appropriately.

A follow-up review will promote better health outcomes and reduce subsequent 999 ambulance call outs.

Benefits to South East Coast Ambulance Service, Surrey Downs CCG & North West Surrey CCG

The project will develop the knowledge and skills of ambulance staff to improve their understanding and recognition of diabetic hypoglycaemia through face to face training and eLearning resources.

Develop and implement a defined pathway for the reporting and subsequent management of patients who have suffered an episode of hypoglycaemia which has resulted in an ambulance call out.

Benefits to MSD

Improved reputation as a collaborative partner to the NHS and provider of healthcare solutions and resources.

Identification of patients at risk of hypoglycaemia who may benefit from alternative oral anti-hyperglycaemic agents including DPP-4 inhibitors as part of a diabetes management review to prevent a subsequent hypoglycaemic event.

Ability to take and share the learnings from this project to other Health Care Organisations to support the integration of diabetes pathways across all relevant stakeholder groups.

Completion date of contractual obligations

January 2016